Publisher： Bentham Science Publishers
E-ISSN： 1873-5576|10|5|519-528
ISSN： 1568-0096
Source： Current Cancer Drug Targets, Vol.10, Iss.5, 2010-08, pp. : 519-528
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Approximately 70% of breast cancers express the estrogen receptor (ER) and endocrine therapy is the most important component of systemic therapy for hormone-responsive breast cancer.Unfortunately, endocrine-resistant ER-positive disease represents up to one-quarter of all breast cancers and a number of different mechanisms have been implicated in endocrine resistance, either intrinsic, occurring de novo at the initial exposure to endocrine therapies or acquired, occurring after an initial response to therapy.In the present work a number of molecular mechanisms accounting for intrinsic and acquired resistance to hormonal therapies have been reviewed and the most promising strategies to overcome endocrine resistance have been highlighted.
Related content
Overcoming Treatment Resistance in HER2-Positive Breast Cancer: Potential Strategies
By Puglisi Fabio >
Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. :
Access to resources
Recommend
Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry, Vol. 18, Iss. 4, 2011-02 ,pp. :
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Current Drug Targets, Vol. 13, Iss. 10, 2012-09 ,pp. :